Revolution Medicines, Inc. Stock Issuance Proceeds increased by 275.1% to $12.21M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1270.3%, from $891.00K to $12.21M. Over 3 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows a downward trend with a -100.0% CAGR.
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Standard for large-cap companies with significant equity-based compensation programs.
proceeds_from_stock_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$564.00K | $0.00 | $0.00 | $0.00 | $0.00 | $323.71M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $727.62M | $891.00K | $1.94M | $4.15M | -$6.97M | $12.21M |
| QoQ Change | — | +100.0% | — | — | — | — | -100.0% | — | — | — | — | — | — | -99.9% | +117.4% | +114.0% | -268.2% | +275.1% |
| YoY Change | — | — | — | — | +100.0% | — | — | — | — | -100.0% | — | — | — | — | — | — | -101.0% | >999% |